Mon, March 23, 2009
Fri, March 20, 2009
Thu, March 19, 2009
Wed, March 18, 2009
Tue, March 17, 2009
Mon, March 16, 2009
Sun, March 15, 2009
Fri, March 13, 2009
Thu, March 12, 2009
Wed, March 11, 2009
Tue, March 10, 2009
Mon, March 9, 2009
Fri, March 6, 2009
Thu, March 5, 2009
Wed, March 4, 2009
Tue, March 3, 2009
Mon, March 2, 2009
Fri, February 27, 2009
Thu, February 26, 2009
Wed, February 25, 2009
Tue, February 24, 2009
Mon, February 23, 2009
Sun, February 22, 2009
Fri, February 20, 2009
Thu, February 19, 2009
[ Thu, Feb 19th 2009 ]: Market Wire
Enzon Reports 2008 Results
Wed, February 18, 2009
Tue, February 17, 2009

Biovail Receives Requisition from Dissident Shareholder Eugene Melnyk


//health-fitness.news-articles.net/content/2009/ .. on-from-dissident-shareholder-eugene-melnyk.html
Published in Health and Fitness on , Last Modified on 2009-02-25 12:24:54 by Market Wire   Print publication without navigation


TORONTO--([ BUSINESS WIRE ])--Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced that it has received a requisition from Eugene Melnyk and a company under his control, EM Holdings B.V. requesting that the Board of Directors call a meeting of shareholders to consider certain matters set out in such requisition. The dissident shareholders are believed to hold sufficient shares of Biovail to be able to requisition a meeting under the Canada Business Corporations Act. They have stated they are seeking to elect two nominees to Biovail's Board of Directors and intend to propose several resolutions for consideration by Biovail shareholders.

Biovail remains committed to considering the views of its shareholders in accordance with the best practices of corporate governance. The Biovail Board of Directors, eight out of ten of whom are independent, will consider the dissident requisition and respond appropriately in due course.

About Biovail Corporation

Biovail Corporation is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products. The Company is focused on the development and commercialization of medicines that address unmet medical needs in niche specialty central nervous system (CNS) markets. For more information about Biovail, visit the Company's Web site at [ www.biovail.com ].

For further information, please contact Nelson F. Isabel at 905-286-3000 or send inquiries to [ ir@biovail.com ].


Publication Contributing Sources